Boston Biomedical
Pharmaceutical ManufacturingMassachusetts, United States51-200 Employees
Boston Biomedical, Inc. is a Cambridge, Massachusetts–based pharmaceutical company focused on developing novel cancer therapeutics and advancing them through discovery, preclinical, clinical, regulatory, and potential commercialization stages. The organization emphasizes an integrated approach to oncology drug development, leveraging its capabilities across medicinal chemistry, pharmacology, chemistry, manufacturing and controls, global clinical trials, and external partnerships to advance multiple compounds and programs aimed at improving patient outcomes. Its work targets cancer patients by progressing therapies with the potential to address cancer stemness pathways and other oncology indications, positioning the company within the wider pharmaceutical manufacturing and oncology research space. The company operates within the pharmaceutical manufacturing and oncology R&D industry, with a corporate environment described as innovation-driven and scientifically oriented. It is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., reflecting a connection to broader global oncology and hematology strategies through this parent organization and its related acquisitions. The firm is based in Cambridge, and its activities include collaboration with external partners and an emphasis on development stages from discovery through regulatory affairs and toward potential commercialization.